Less than three months after going public via a $227.7 million IPO, shares of Bioage Labs Inc. (NASDAQ:BIOA) took a hit Dec. 9, losing 77% of their value, as safety concerns prompted the company to halt its phase II trial testing oral obesity candidate azelaprag. The Strides study, launched in July, had been testing azelaprag, an oral apelin receptor agonist licensed from Amgen Inc., as a monotherapy and in combination with GLP-1/GIP therapy Zepbound (tirzepatide, Eli Lilly and Co.) in obesity.
Mobile health platform company Helfie AI has partnered with Microsoft to offer Microsoft enterprise customers the ability to license Helfie’s cutting-edge health assessment tools directly through the Microsoft Azure Marketplace.
Nearly 80% of people in Australia and the U.S. that used Genetic Technologies Ltd.’s Genetype multi-risk assessment test showed an elevated risk for at least one disease covered by the test.
